Open AccessUse of etidronate (ehdp) in paget's disease of bone
Author(s) -
Johnston C. Conrad,
Khairi M. R. A.,
Meunier P. J.
Publication year - 1980
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.1780231015
Subject(s) - hydroxyproline , etidronic acid , medicine , bone resorption , alkaline phosphatase , urology , urinary system , paget's disease of bone , osteoid , gastroenterology , osteoporosis , endocrinology , disease , chemistry , biochemistry , enzyme
Etidronate used in recommended doses (usually 5 mg/kg/day for 6 months) produces symptomatic improvement in approximately 60% of patients. The serum alkaline phosphatase and urinary hydroxyproline are reduced to about 50% of initial values. A sustained remission occurs in many patients and retreatment is usually effective upon relapse. The abnormally elevated osteoclast count and resorption surfaces are reduced, and at the low dose there is no accumulation of osteoid. The medication is generally well tolerated and at the recommended dosage there is no evidence of increased fracture rate.